In vivo synergy of vitamin K3 and methotrexate in tumor-bearing animals.
In vivo synergy was demonstrated with vitamin K3 (menadione) and methotrexate in rats bearing the Walker 256 im carcinosarcoma, without concomitant increase in toxicity. Synergy is defined as a combined antitumor effect which exceeds the sum of the individual antitumor effects. It is suggested that such synergy, extended to human neoplasms, may significantly increase the effectiveness of methotrexate as a chemotherapeutic agent.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D008727:Methotrexate / Q000627:therapeutic use*; D051381:Rats; D014812:Vitamin K / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D024483:Vitamin K 3
D014812:Vitamin K; D024483:Vitamin K 3; D008727:Methotrexate